Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B - Seite 3

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References
[1] Sante et Services Sociaux. Vaccination. Available at http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php?accue .... Accessed July 2014.
[2] Agence de la santé et des services sociaux du Saguenay-Lac-Saint-Jean. First wave of vaccination against meningococcal B (press release). June 19, 2014. Available at: http://www.csrsaguenay.qc.ca/medias/csrsaguenay/fichiers/Actualite/Com .... Accessed July 2014.
[3] European Medicines Agency. Authorization Details for Bexsero. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi .... Accessed July 2014.
[4] European Medicines Agency. EU Member States. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_network .... Accessed July 2014.
[5] Australian Government: Department of Health: Therapeutic Goods Administration. Available at: http://www.tga.gov.au/pdf/auspar/auspar-meningococcal-131031.pdf. Accessed July 2014.
[6] Health Canada. Bexsero. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_201 .... Accessed June 2014.
[7] Gilca et al. The Changing Epidemiology of Meningococcal Disease in Quebec, Canada, 1991-2011: Potential Implications of Emergence of New Strains. November 2012. Available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.005 .... Accessed June 2014.
[8] Perrett KP, Pollard AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opinion on Biological Therapy. 2005, 5: 1611-1625. Available at: http://informahealthcare.com/doi/abs/10.1517/14712598.5.12.1611. Accessed July 2014.